Department of Health Service Management, Iran University of Medical Sciences, 1968643513 Tehran, Iran.
Med Oncol. 2011 Dec;28 Suppl 1:S70-4. doi: 10.1007/s12032-010-9714-x. Epub 2010 Oct 26.
The aim of this study was to compare the differences between the level of whole quality of life and its subscales after receiving two common treatment of breast cancer in women with early stage of breast cancer. A double-blinded cohort study was done in 100 breast cancer patients with node positive that used fluorouracil, doxorubicin, cyclophosphamide (FAC) and docetaxel, doxorubicin and cyclophosphamide (TAC) regimen as adjuvant therapy. Patients were followed for 4 months since the end of chemotherapy. Health-related quality of life was assessed using questionnaire (QLQ-C30) from European Organization for Research and Treatment of Cancer (EORTC). Independent t-test analysis was used at the significant level of 0.05 for analyzing the results. The mean of age was 48.49 ± 10.63 in these patients. QoL scores were 64 and 68 in TAC and FAC groups, respectively (P < 0.001). After 4 months, patients in TAC and FAC groups experienced 11.45 and 7.14 units of improvement in QoL scores, respectively (P = 0.02). Although, TAC had a more negative impact on QoL during chemotherapy, it created a higher improvement than FAC during 4 months since the end of treatment. These effects on quality of life should be considered in making decision for providing and financing cancer treatments in Iran.
本研究旨在比较早期乳腺癌女性接受两种常见乳腺癌治疗后的整体生活质量及其子量表水平的差异。对 100 例淋巴结阳性乳腺癌患者进行了一项双盲队列研究，这些患者使用氟尿嘧啶、多柔比星、环磷酰胺（FAC）和多西他赛、多柔比星和环磷酰胺（TAC）方案作为辅助治疗。患者在化疗结束后随访 4 个月。采用欧洲癌症研究与治疗组织（EORTC）的问卷（QLQ-C30）评估健康相关生活质量。采用独立样本 t 检验分析，显著水平为 0.05。这些患者的平均年龄为 48.49 ± 10.63 岁。TAC 和 FAC 组的 QoL 评分分别为 64 和 68（P < 0.001）。4 个月后，TAC 和 FAC 组患者的 QoL 评分分别改善了 11.45 和 7.14 个单位（P = 0.02）。尽管 TAC 在化疗期间对 QoL 有更负面的影响，但在治疗结束后 4 个月内，它的改善程度高于 FAC。在为伊朗的癌症治疗提供和融资做出决策时，应考虑这些对生活质量的影响。
